Monitor Unbuzzd's sales execution and distribution milestones as a proxy for future royalty income; any material revenue traction could revalue Quantum's stake given its $20M market cap.
Price Chart
Executive Summary
Quantum Biopharma Ltd. announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc., its licensed OTC hangover remedy brand, marking a key step in commercialization with plans for nationwide U.S. rollout and potential stock exchange listing. Quantum retains a 19.84% stake and 7% royalty on sales until $250 million in payments, dropping to 3% thereafter.
Key Facts
- Unbuzzd Wellness Inc. appointed Richard Buzbuzian as CEO to lead U.S. commercialization.
- Nationwide rollout to begin in South Florida and Texas, with plans for stock exchange listing.
- unbuzzd is clinically validated by a peer-reviewed study published in 2026.
- Quantum BioPharma retains 19.84% ownership in Unbuzzd Wellness Inc. as of December 31, 2025.
- Royalty agreement: 7% of sales until $250 million paid to Quantum, then drops to 3% in perpetuity.
Financial Impact
Potential future royalty revenue up to $250 million at 7%, then 3% in perpetuity; no immediate financial impact disclosed.
Risk Factors
- Execution risk in nationwide rollout and market acceptance.
- Dependence on Unbuzzd's ability to secure retail partnerships and scale operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002639 |
| Document: f6k_042226.htm | 0001171843-26-002639 |
| Document: 0001171843-26-002639-index-headers.html | 0001171843-26-002639 |
| Document: 0001171843-26-002639-index.html | 0001171843-26-002639 |
| Document: 0001171843-26-002639.txt | 0001171843-26-002639 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers